Resources from the same session
32O - 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the Phase III PAOLA-1/ENGOT-ov25 trial
Presenter: Domenica Lorusso
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
33O - PRIMA/ENGOT-OV26/GOG-3012 study: long-term conditional PFS
Presenter: Antonio Jose Gonzalez Martin
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
34O - ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss - results from the ENGOT/GYN1/NCRI ATARI trial
Presenter: Susana Banerjee
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstract 34O
Presenter: Jean Emmanuel Kurtz
Session: Proffered Paper session
Resources:
Slides
Webcast
35O - Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer Adjusted for Subsequent PARPi Use in Placebo Group: Results from an Ad Hoc Interim Analysis for the Phase 3 NORA Study
Presenter: Xiaohua Wu
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstract 35O
Presenter: Jonathan Ledermann
Session: Proffered Paper session
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Proffered Paper session
Resources:
Webcast